Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient.

Merrill, Patrick Joseph; Bradburne, R Mark

Merrill, Patrick Joseph; Bradburne, R Mark.

Merrill PJ; Department of Cardiology, Riverside Kaiser Hospital, Southern California Permanente Medical Group, Riverside, CA.
Bradburne RM; Department of Pulmonology, Riverside Kaiser Hospital, Southern California Permanente Medical Group, Riverside, CA.

Perm J ; 252021 12 14.

Article in English | MEDLINE | ID: covidwho-1766163

ABSTRACT

ABSTRACT

This case report describes a successful outcome involving a patient with severe COVID-19 viral pneumonia utilizing a novel therapeutic approach with the glycoprotein IIb/IIIa inhibitor, eptifibatide.

Subject(s)

COVID-19 Drug Treatment; Eptifibatide; Humans; Peptides/therapeutic use; Platelet Aggregation Inhibitors/therapeutic use; Platelet Glycoprotein GPIIb-IIIa Complex

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Case report / Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: TPP

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google